Research map: Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Glucocorticoids: A Real-World Pharmacovigilance Analysis

Back to the article

Papers in this map

  1. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial · Javier Cortés · 2020 · 1858 citations · Cited by this paper
  2. Real-World Evaluation of a Pneumonia PCR Panel: Appropriateness, Outcomes, and Antimicrobial Stewardship Implications · 2025 · Related
  3. Immune checkpoint inhibitors in melanoma · Matteo Salvatore Carlino · 2021 · 1235 citations · Cited by this paper
  4. Characterization of Electronic Missing Medication Requests to Identify Medication-Use System Vulnerabilities and Interprofessional Workflow Targets · 2026 · Related
  5. Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications · Biagio Ricciuti · 2019 · 334 citations · Cited by this paper
  6. Effects of Telepharmacy in Post Ischemic Stroke Patients: A Randomized Controlled Trial · 2026 · Related
  7. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy · Xue Li Bai · 2021 · 186 citations · Cited by this paper
  8. Drug-Related Problems in Outpatient Prescriptions Across Different Levels of Care in Vietnam: A Multicentre Cross-Sectional Study in a Resource-Constrained Health System · 2026 · Related
  9. Use of data mining at the Food and Drug Administration · Hesha Jani Duggirala · 2015 · 153 citations · Cited by this paper
  10. Hypotensive Events Associated With PDE-5 Inhibitors in Pulmonary Arterial Hypertension: Assessment of the USFDA Adverse Event Reporting System Using Disproportionality and Interaction Analysis · 2026 · Related
  11. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system · Chen Chen · 2021 · 135 citations · Cited by this paper
  12. Identifying and Resolving Drug-Related Problems in Geriatric Patients · 2026 · Related
  13. Opportunistic infections in patients treated with immunotherapy for cancer · Chrisann Kyi · 2014 · 120 citations · Cited by this paper
  14. Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient · 2026 · Related
  15. Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems · Yoshihiro Noguchi · 2020 · 95 citations · Cited by this paper
  16. Impact of Peripheral Rabbit Anti-Thymocyte Globulin Without Heparin and Hydrocortisone Additives on Local Infusion Reactions · 2026 · Related
  17. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study · Toni K. Choueiri · 2024 · 77 citations · Cited by this paper
  18. Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice · 2026 · Related
  19. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer · Rebecca Alexandra Dent · 2024 · 62 citations · Cited by this paper
  20. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition · Barbara Renga · 2012 · 58 citations · Cited by this paper
  21. Endurance exercise training increases adipose tissue glucocorticoid exposure: adaptations that facilitate lipolysis · Jonathan Edward Campbell · 2009 · 50 citations · Cited by this paper
  22. Glucocorticoids Repress Transcription of Phosphoenolpyruvate Carboxykinase (GTP) Gene in Adipocytes by Inhibiting Its C/EBP-mediated Activation · Yael Olswang · 2003 · 39 citations · Cited by this paper
  23. Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options · Carmen Portenkirchner · 2021 · 29 citations · Cited by this paper
  24. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors · Nijiao Li · 2023 · 23 citations · Cited by this paper
  25. Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center · Natalie Farha · 2023 · 22 citations · Cited by this paper
  26. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review · Thomas M. Ruli · 2024 · 19 citations · Cited by this paper
  27. Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression · Julian Swatler · 2023 · 16 citations · Cited by this paper
  28. Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer · Hui Yu · 2023 · 15 citations · Cited by this paper
  29. Glucocorticoid activates STAT3 and NF-κB synergistically with inflammatory cytokines to enhance the anti-inflammatory factor TSG6 expression in mesenchymal stem/stromal cells · Peiqing Huang · 2024 · 14 citations · Cited by this paper
  30. Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors · Yasunori Fujita · 2023 · 7 citations · Cited by this paper
  31. Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors · Karlijn de Joode · 2023 · 7 citations · Cited by this paper
  32. Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database · Lin Cao · 2026 · 4 citations · Cited by this paper
  33. The dual role of glucocorticoids in the breast cancer immune microenvironment: mechanisms and therapeutic implications · Bianping Liang · 2025 · 2 citations · Cited by this paper
  34. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer · Francesca Jackson‐Spence · 2026 · 2 citations · Cited by this paper
  35. Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS · Caihong Qu · 2026 · 2 citations · Cited by this paper
  36. A Retrospective Study on the Clinical Characteristics and Management of Immune-Related Adverse Events in Gynecologic Cancer Patients Treated with Immune Checkpoint Inhibitors · Yu Xia · 2026 · 1 citation · Cited by this paper
  37. Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS database · Connor Frey · 2026 · 1 citation · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)